Lupin Ltd.


  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Feb 19, 2018
Prev close: 816.2
Feb 19, 2018
Market cap:
Market cap(USD):
Shares: 452.05M

Currency in INR

Company profile

Market(Ticker): BOM(500257)
Health Technology
Pharmaceuticals: Generic
Full time employees: 22,037

Business summary

Lupin Ltd. operates as a pharmaceuticals company. It manufactures and distributes pharmaceutical ingredients and formulations. The company offers products in growth therapy segments, such as cardiology, central nervous system, anti-diabetic, anti-TB, anti-asthma, gynaecology, anti-infective, gastro-intestinal and others. Lupin was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Company background

Lupin is a major generic drugmaker that conducts business in more than 100 countries. Among India's five biggest pharmaceuticals, it has about 10 production bases in India and exports generic drugs to other countries.

It was founded in 1968 by Desh Bandhu Gupta, a researcher at a science university. Since the early 2000s, it has been actively buying companies in South Africa, Mexico, even Japan.

It got a head start on its Indian competitors by building a supply network in Japan. It did so in 2007 by acquiring Kyowa Pharmaceutical Industry, an Osaka-based medium-size generic drugmaker. In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.

Zyma Laboratories, an affiliate company run by Desh Bandhu Gupta and other executives, is Lupin's top shareholder; the founding family still owns some shares in Lupin.

In the news

Financial highlights

Mar 2017

  • Local currency
  • US Dollar
Revenue 170,305.3M
Gross profit 83,802.2M
Operating income 37,023.7M
Income before tax 35,348.9M
Net income 25,574.6M
EBITDA 46,146M
Diluted EPS 56.46
Dividends per share 7.5
Total assets 266,072.8M
Total liabilities 130,751.9M
Total equity 134,966.5M
Operating cash flow 40,105.2M

Currency in INR

Revenue 2,539.70M
Gross profit 1,249.71M
Operating income 552.12M
Income before tax 527.14M
Net income 381.38M
EBITDA 688.16M
Diluted EPS 0.84
Dividends per share 0.11
Total assets 4,097.52M
Total liabilities 2,013.58M
Total equity 2,078.48M
Operating cash flow 598.07M

Currency in USD

Valuation measures

Mar 2017

PER 25.48
ROA 10.38%
ROE 20.74%
Operating margin 21.73%
Profit margin 15.01%

Key executive

  • Managing Director & Executive Director: Nilesh Deshbandhu Gupta
  • Chief Executive Officer & Executive Director: Vinita D. Gupta
  • Chief Financial Officer & Executive Director: Ramesh Swaminathan
  • President-Technical Operations: Alok Ghosh
  • Secretary & Compliance Officer: Rajvardhan V. Satam

Share holders

  • Lupin Investments Pvt Ltd.(45.4%)
  • Life Insurance Corp. of India(2.6%)
  • First State Investment Management (UK) Ltd.(2.4%)
  • Genesis Investment Management LLP(2.4%)
  • The Vanguard Group, Inc.(1.6%)
  • ICICI Prudential Asset Management Co. Ltd.(1.5%)
  • BlackRock Fund Advisors(1.5%)
  • Norges Bank Investment Management(1.2%)
  • Fidelity Management & Research Co.(1.0%)


  • Website:
  • Address: Laxmi Towers, Bandra Kurla Complex, Mumbai, 400051, India
  • Phone: +91.22.66402222

Copyright © 2018 FactSet Research Systems Inc. All rights reserved.